2026-11-05

November 5, 2026 | Medicare payment cuts, rebate preparation and claims-data disputes

340B policy is moving across payment, purchasing and data requirements, while covered entities contest how program savings are handled. On November 4, CMS finalized its 2027 outpatient rule, raising qualifying hospitals’ outpatient payment rates by 2.3% while cutting payment for 340B-acquired drugs. The University of Kentucky and Ashland Hospital Corporation sued CVS Health and affiliates on October 27, alleging diversion of more than $41 million in 340B savings. Five Massachusetts hospitals sued Lilly the same day, alleging it unlawfully ended 340B discounts after they refused to provide patient claims data. Separately, HRSA approved rebate pilot plans covering 21 drugs from 10 manufacturers, requiring full-price purchases before rebates beginning January 1 unless a court or Congress stops the change. Together, these developments put payment levels, control over savings and access to claims data at issue, as hospitals challenge CVS and Lilly and the rebate pilot creates a new purchasing sequence for covered entities.

EXECUTIVE SUMMARY
01
CMS finalizes 2027 outpatient rule with 340B drug payment cuts.
CMS finalized the rule November 4, raising qualifying hospitals’ outpatient payment rates 2.3% while cutting payment for 340B-acquired drugs.

02
University of Kentucky alleges CVS diverted more than $41 million.
The university and Ashland Hospital Corporation sued CVS Health and affiliates October 27 over alleged diversion of 340B savings.

03
Five Massachusetts hospitals challenge Lilly’s claims-data demands.
The hospitals sued October 27, alleging Lilly unlawfully cut off 340B discounts after they refused to provide patient claims data.

04
Rebate pilot covers 21 drugs from 10 manufacturers.
HRSA approved plans that would require full-price purchases before rebates beginning January 1, unless a court or Congress stops the change.

05
Missouri gives Lilly a November 26 deadline.
Attorney General Catherine Hanaway’s October 26 cease-and-desist letter asked Lilly to end its claims-data policy by November 26.

Source: STAT

06
ASPE challenges 340B financial incentives.
Its October 8 report found inflation-adjusted payments for 340B drugs furnished by non-exempt providers rose from $7.1 billion to $10.7 billion during 2021-2023.

Source: HHS ASPE

07
PBM reform has a longer implementation schedule.
AJMC reports most CAA 2026 PBM provisions take effect for plan years beginning on or after August 3, 2028, or January 1, 2029, for calendar-year plans.

EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. For covered entities, the 2.3% increase in qualifying hospitals’ outpatient payment rates must be distinguished from the separate cut to payment for 340B-acquired drugs; the rate increase does not restore those drug payments. The lawsuits also put the handling of 340B savings and claims-data conditions into dispute, while the approved rebate plans would require covered entities to purchase participating drugs at full price before receiving rebates beginning January 1, unless a court or Congress stops the change. These are distinct payment, data and purchasing issues, and covered entities should assess each against the terms and timing described in the rule, litigation and pilot plans.
Emerging risks.

  • Becker’s reports that the January 1 pilot would require hospitals to pay full price for 21 drugs before receiving 340B rebates.
  • Five Massachusetts hospitals allege Lilly cut off discounts after they refused patient claims-data demands; their October 27 lawsuit remains an active dispute.
  • The University of Kentucky and Ashland Hospital Corporation allege CVS companies diverted more than $41 million in 340B savings.
  • CMS finalized lower payment for 340B-acquired drugs on November 4, but the supplied report does not specify the final payment formula.
Emerging opportunities.

  • HRSA requires manufacturers to make quarterly ceiling-price files available by 11-digit NDC for Medicaid billing, sliding-fee calculations or patient cost sharing.
  • HRSA specifies unit-level rebates rather than accumulation of a full package, giving covered entities a stated basis for rebate reconciliation.
  • The PROTECT 340B Act would prohibit lower reimbursement, extra fees and contract-pharmacy network exclusions based on 340B participation.
  • AJMC reports a November 23 response deadline for CMS’s request for information on pharmacy reimbursement terms in PBM contracts.
Key actions for providers.

  • Separate the November 4 final-rule payment cut from ASPE’s October 8 discussion of the proposed ASP-minus-33.4% formula.
  • Use HRSA’s dispense-date ceiling price and unit-level methodology when reviewing rebate reconciliation requirements.
  • Track January 1 negotiated-price changes alongside the pilot’s planned transition for drugs subject to both changes.
  • Monitor Lilly’s response to Missouri Attorney General Catherine Hanaway’s November 26 deadline to end its claims-data policy.
TOP STORIES
CMS finalizes outpatient payment increases and 340B drug cuts
Becker’s Hospital Review · November 5, 2026
  • CMS finalized its 2027 hospital outpatient and ASC payment rule November 4.
  • Outpatient payment rates rise 2.3% for hospitals that meet quality reporting requirements.
  • The increase combines a 3.2% market basket update and a 0.9-percentage-point productivity adjustment.
  • The rule cuts payment for 340B-acquired drugs and expands site-neutral payments to imaging.
  • CMS continues to phase out the inpatient-only list.
University of Kentucky sues CVS companies over alleged diversion of 340B savings
Becker’s Hospital Review · October 30, 2026
  • The University of Kentucky and Ashland Hospital Corporation sued CVS Health and affiliates October 27.
  • The plaintiffs allege the companies diverted more than $41 million in 340B savings from the health system.
  • The complaint names CVS Health, CaremarkPCS Health, Caremark d/b/a CVS Specialty and WellPartner.
  • The plaintiffs filed in the U.S. District Court for the Eastern District of Kentucky.
  • Ashland Hospital Corporation operates UK King’s Daughters Medical Center.
Massachusetts hospitals sue Lilly over claims-data conditions
Becker’s Hospital Review · October 27, 2026
  • Five Massachusetts hospitals sued Eli Lilly October 27 in the U.S. District Court for the District of Massachusetts.
  • The hospitals allege Lilly unlawfully cut off their 340B discounts after they refused to provide patient claims data.
  • The complaint alleges violations of Massachusetts’ consumer protection law and unjust enrichment.
  • Plaintiffs include Massachusetts General Hospital, Brigham and Women’s Hospital and North Shore Medical Center (Salem Hospital).
  • UMass Memorial Medical Center and UMass Memorial Health-Harrington Hospital also joined the suit.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
House bill targets PBM and insurer discrimination against 340B participants
Becker’s Hospital Review · November 2, 2026
  • Reps. Doris Matsui and Tracey Mann introduced the bipartisan PROTECT 340B Act October 29.
  • The bill would prohibit lower reimbursement for 340B drugs and extra fees on covered entities and their contract pharmacies.
  • The bill would prohibit contract-pharmacy network exclusions and other discriminatory conditions based on program participation.
  • The Association of American Medical Colleges and other hospital groups endorsed the bill.
AHA supports SUSTAIN 340B Act but requests revisions
Becker’s Hospital Review · October 29, 2026
  • The American Hospital Association requested revisions to the SUSTAIN 340B Act in an October 27 letter to its six Senate sponsors.
  • The AHA supports provisions to codify contract-pharmacy use and establish a data clearinghouse.
  • The six senators introduced the bill August 5.
  • Sponsors include Jerry Moran, Tammy Baldwin, Shelley Moore Capito, Tim Kaine, John Boozman and John Hickenlooper.
340B PROGRAM DEVELOPMENTS
Rebate pilot plans cover 21 drugs ahead of January 1
Becker’s Hospital Review · October 26, 2026
  • HRSA approved rebate plans from 10 manufacturers covering 21 drugs for its revised pilot.
  • Hospitals would pay full price upfront and receive their 340B discounts later as rebates.
  • The change is scheduled for January 1 unless a court or Congress stops it.
  • Covered entities would continue purchasing through their 340B wholesaler accounts.
  • Participating manufacturers include AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Merck, Pfizer and Teva.
LITIGATION & ENFORCEMENT WATCH
Court Matter Date
U.S. District Court for the Eastern District of Kentucky University of Kentucky sues CVS over alleged $41M 340B scheme; the university and Ashland Hospital Corporation filed October 27. The supplied item does not print a formal case caption or docket number. [source] 2026-10-30
U.S. District Court for the District of Massachusetts 5 Massachusetts hospitals sue Eli Lilly over 340B data demands; the hospitals filed October 27. The supplied item does not print a formal case caption or docket number. [source] 2026-10-27
MANUFACTURER WATCH
Manufacturer Action Date
Eli Lilly Five Massachusetts hospitals alleged October 27 that Lilly cut off 340B discounts after they refused to provide patient claims data. [source] 2026-10-27
Amgen HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] 2026-10-26
Astellas HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] 2026-10-26
AstraZeneca HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] 2026-10-26
Bristol Myers Squibb HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] 2026-10-26
Boehringer Ingelheim HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] 2026-10-26
GSK HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] 2026-10-26
Merck HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] 2026-10-26
Pfizer HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] 2026-10-26
Teva HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] 2026-10-26
SOCIAL MEDIA & STAKEHOLDER SENTIMENT

The review screened material dated August 7 through November 5, 2026, and retained distinct, directly accessible statements, named commentary, and public social discussion; it excluded duplicate and undated material.

Reform the 340B Rebate Model to Protect Health Centers
Substack, Advocates for Community Health · September 17, 2026
  • Main theme: Jordan Valley Health CEO Matthew Stinson supports reform goals but calls for safeguards against rebate delays, disputed claims, and added health-center costs.
  • Stakeholder sentiment: Health-center provider view: concerned but open to reform. Stinson writes, “FQHCs do not oppose reform.”
  • Potential implications: His proposed safeguards include timely payment enforcement, common data rules, and protections for health centers with limited cash reserves.
  • Credibility: A first-person policy essay by a named FQHC leader; it is useful for the provider’s position, not independent evidence of program effects.
Accountability in the 340B Drug Pricing Program
Third Way · November 2, 2026
  • Main theme: Gaby Hartney compares rebate and clearinghouse models as ways to improve transaction checks, while noting possible cash-flow strain for providers.
  • Stakeholder sentiment: Policy-commentary view: supportive of stronger transaction oversight, with caution about effects on rural and smaller providers. Hartney writes, “The two models have tradeoffs.”
  • Potential implications: The memo puts provider liquidity alongside transaction-level accountability in the debate over program changes.
  • Credibility: A dated policy memo by a named Third Way author that cites outside sources; it is advocacy analysis, not peer-reviewed research.
The Paradox of Hospital Pharmacy
Reddit, r/pharmacy · September 8, 2026
  • Main theme: Commenters discuss hospital pharmacy finances, with one linking 340B to pharmacy margins and the forthcoming rebate proposal.
  • Stakeholder sentiment: Anonymous pharmacy-worker discussion: concerned about the rebate proposal’s financial effect. One commenter wrote, “With 340b it’s about to be a loss starting 2027 with the new proposal of reimbursement.”
  • Potential implications: The thread signals concern among some pharmacy participants about whether hospitals can sustain current pharmacy operations under the proposal.
  • Credibility: Public user-generated discussion with no verified identities; it shows individual sentiment and is not representative evidence.
WHAT TO WATCH NEXT
  • November 23: AJMC reports that responses are due to CMS’s request for information on pharmacy reimbursement terms in PBM contracts. [source]
  • November 26: Missouri Attorney General Catherine Hanaway asked Lilly to end its claims-data policy by this date. [source]
  • January 1: The 21-drug rebate pilot is scheduled to begin unless a court or Congress stops the change. [source]
  • January 1: Medicare negotiated prices take effect for 15 more drugs, several of which also face rebate-only 340B pricing. [source]
  • 2027: CMS’s finalized outpatient rule raises qualifying hospitals’ payment rates 2.3% and cuts payment for 340B-acquired drugs. [source]
End of briefing.

This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.

© 2026 MedMatrix Rx. All rights reserved.

Post information

Schedule Your 340B Assessment

Connecting healthcare organizations to their full potential through compliant 340B optimization.